Anzeige
Mehr »
Login
Sonntag, 01.12.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Der verborgene Hebel im Moss-Projekt von Goldshore: Warum 13,9?Mio.?$ eine goldene Zukunft freisetzen könnten
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
399 Leser
Artikel bewerten:
(2)

Modular Medical, Inc.: Modular Medical Relocates to Larger Corporate Headquarters

Finanznachrichten News

The 7,300 square foot facility features a clean-room manufacturing environment and environmentally controlled test labs

SAN DIEGO, CA / ACCESSWIRE / March 16, 2021 / Modular Medical, Inc. (OTCQB:MODD), a development-stage company focused on the next generation of easy to use, affordable insulin pumps to expand access to high end insulin delivery technology to a large, underserved portion of the diabetes market, today announced it has relocated to a new corporate headquarters building in San Diego CA. The larger facilities accommodate expanded staffing to enable the increased level of R&D and testing activity necessary to support the company's 510(k) submission later this year.

"A clean room environment for low-volume component manufacturing adds a valuable dimension to support our R&D efforts," said Marc Goldman, Vice President of R&D at Modular Medical. "Additionally, access to an in-house environmentally controlled test lab gives our engineers capability to run on-demand accuracy validation studies. This gives us an important efficiency we wouldn't otherwise see," he added.

By choosing to remain in the greater San Diego area, an established center of medical device and healthcare innovation, the company maintains access to a rich talent pool of professionals across an array of technical disciplines. The company currently has a staff of 20 and plans to fill several additional key positions in the coming months.

"I'm pleased to see how much we've grown as a team and as a company," said Paul DiPerna, the founder and Chief Executive Officer of Modular Medical. "Our move came at a pivotal time in the development of our technology. With the completion of our design and ongoing validation of our interface and feature set, we are now well positioned to begin the extensive testing and usability that regulatory bodies require."

About Modular Medical, Inc.

Modular Medical, Inc. (OTCQB:MODD) is a development-stage diabetes technology company based in San Diego CA. Working from an innovative set of patented technologies, Modular seeks to expand access to high end diabetes technologies to the neglected majority of the diabetes market. These people have been poorly served by the existing options that are often too expensive and complex to drive broad adoption. Modular Medical's novel approach is to provide care at a level of cost and complexity not for "superusers" but for "the rest of us". Modular Medical was founded by CEO Paul DiPerna, a seasoned medical device professional and world-class microfluidics engineer. Mr. DiPerna was previously the founder (in 2005) of Tandem Diabetes (TNDM) and invented and designed their T:slim insulin pump.

More information is available at https://modular-medical.com.

Forward-Looking Statements

This press release may contain forward-looking statements about Modular Medical, including, without limitation, the timing of its FDA submission and hiring plans. Forward-looking statements are based on certain assumptions and expectations of future events that are subject to risks and uncertainties. Such statements are made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results and trends may differ materially from historical results or those projected in any such forward-looking statements depending on a variety of factors. These factors include, but are not limited to, the company's ability to make its 510(k) submission and fill positions during 2021 and other risks identified in the company's most recent reports on forms 10-Q and 10-K filed with the Securities and Exchange Commission, as well as other reports that the company files from time to time with the Securities and Exchange Commission. Modular Medical undertakes no obligation to update publicly any forward-looking statement for any reason, except as required by law, even as new information becomes available or other events occur in the future.

All trademarks mentioned herein are the property of their respective owners.

CONTACT:

Investor Relations
Modular Medical, Inc.
+1 (858) 800-3500
IR@modular-medical.com

SOURCE: Modular Medical, Inc.



View source version on accesswire.com:
https://www.accesswire.com/635707/Modular-Medical-Relocates-to-Larger-Corporate-Headquarters

© 2021 ACCESSWIRE
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.